Celaid Therapeutics and AGC sign iPSC-HSPC research deal

Celaid Therapeutics Inc. Celaid has teamed up with AGC Inc. for a collaborative research agreement. AGC focuses on advancing hematopoietic stem and progenitor cells from induced pluripotent stem cells (iPSC-HSPCs). The partnership aims to combine Celaid’s unique hematopoietic stem cell (HSC) expansion platform with AGC’s iPSC technology. This will allow for better and larger-scale growth of iPSC-HSPCs.

Celaid’s HSC expansion technology will be used with AGC’s iPSC-HSPCs. The expanded cells will then be tested for functionality in the lab and in animal studies. The initiative seeks to create a way for large-scale production of high-quality iPSC-HSPCs. It aims to tackle important manufacturing challenges in developing iPSC-based blood and immune cell therapies.

Also Read: Asahi Kasei Opens New Plant to Boost Planova Output

“We’re excited to team up with AGC. Together, we’ll use advanced stem cell technologies for future breakthroughs,” said Nobuyuki Arakawa, President and CEO of Celaid Therapeutics. “This collaboration is a big step toward solving the main challenges in making iPSC-derived hematopoietic and immune cell therapy products.””